Semaglutide |
| Catalog No.GC31404 |
Semaglutide는 장작용 인간 GLP-1(GLP-1) 유사물질이자 인간 GLP-1 수용체의 가동제이다.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 910463-68-2
Sample solution is provided at 25 µL, 10mM.
Semaglutide는 장작용 인간 GLP-1(GLP-1) 유사물질이자 인간 GLP-1 수용체의 가동제이다. 이것은 혈당, 체중 및 혈압을 낮추고 성인 2형 당뇨병 환자의 혈당 조절을 개선한다[1-2].
Semaglutide (900nM; 24시간)은 BV2 세포에서 NLRP3 인플라마소 활성을 차단하여 LPS 및 니게리신 유도된 인플러매토리 응답과 LDH 방출을 완화시켰다[3]. Semaglutide (5nM; 30분)는 H/R H9C2 세포에서 GLP1R의 표현을 촉진하고 PKG/PKCε/ERK1/2 신호 전달 경로를 활성화시켰다[4].
Semaglutide (40µg/kg, 3일에 한 번; 4주; 피하 주사)는 비만 쥐의 외부eWAT의 지방세포에서 상당한 항염증 효과를 나타내고 내피질망 스트레스를 완화시켰습니다[5]. Semaglutide (30nmol/kg/일; 복강 주사; 12주간)는 비만 쥐의 체중을 감소시키고 혈당 대사, 염증 및 산화 스트레스를 개선시켰다[6]. Semaglutide (0.1mg/kg; 복강 주사)는 SIRT1 경로를 통해 3xTg 쥐의 혈당을 감소시켜 뇌의 혈당 대사를 촉진했다[7].
References:
[1]. FrÍas JP, Davies MJ, et, al. SURPASS-2 Investigators. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021 Aug 5;385(6):503-515. doi: 10.1056/NEJMoa2107519. Epub 2021 Jun 25. PMID: 34170647.
[2]. Chao AM, Tronieri JS, et, al. Semaglutide for the treatment of obesity. Trends Cardiovasc Med. 2023 Apr;33(3):159-166. doi: 10.1016/j.tcm.2021.12.008. Epub 2021 Dec 21. PMID: 34942372; PMCID: PMC9209591.
[3]. Wang L, Ding J, et, al. Semaglutide attenuates seizure severity and ameliorates cognitive dysfunction by blocking the NLR family pyrin domain containing 3 inflammasome in pentylenetetrazole‑kindled mice. Int J Mol Med. 2021 Dec;48(6):219. doi: 10.3892/ijmm.2021.5052. Epub 2021 Oct 22. PMID: 34676876; PMCID: PMC8547541.
[4]. Zhu Q, Luo Y, et, al. Semaglutide inhibits ischemia/reperfusion-induced cardiomyocyte apoptosis through activating PKG/PKCε/ERK1/2 pathway. Biochem Biophys Res Commun. 2023 Mar 5;647:1-8. doi: 10.1016/j.bbrc.2023.01.049. Epub 2023 Jan 17. PMID: 36706596.
[5]. Martins FF, Marinho TS, et, al. Semaglutide (GLP-1 receptor agonist) stimulates browning on subcutaneous fat adipocytes and mitigates inflammation and endoplasmic reticulum stress in visceral fat adipocytes of obese mice. Cell Biochem Funct. 2022 Dec;40(8):903-913. doi: 10.1002/cbf.3751. Epub 2022 Sep 28. PMID: 36169111.
[6]. Pan X, Yang L, et, al. Semaglutide ameliorates obesity-induced cardiac inflammation and oxidative stress mediated via reduction of neutrophil Cxcl2, S100a8, and S100a9 expression. Mol Cell Biochem. 2023 Jun 15. doi: 10.1007/s11010-023-04784-2. Epub ahead of print. PMID: 37318712.
[7]. Wang ZJ, Li XR, et, al. Semaglutide ameliorates cognition and glucose metabolism dysfunction in the 3xTg mouse model of Alzheimer's disease via the GLP-1R/SIRT1/GLUT4 pathway. Neuropharmacology. 2023 Dec 1;240:109716. doi: 10.1016/j.neuropharm.2023.109716. Epub 2023 Sep 18. PMID: 37730113.
Average Rating: 5 (Based on Reviews and 4 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *